The effects of reference pricing and other drug pricing policies

Morten Aaserud; Astrid A. Dahlgren; Jan Peter Kosters; Heidrun Strum; Craig R Ramsay; Andrew D. Oxman

The effects of reference pricing and other drug pricing policies

Morten Aaserud, Astrid A. Dahlgren, Jan Peter Kosters, Heidrun Strum, Craig R Ramsay, Andrew D. Oxman

Research output: Contribution to journal › Article › peer-review

Abstract

We carried out a systematic review on studies of effects of pharmaceutical pricing policies. Ten studies of reference pricing and one study of index pricing were included. Based on the evidence in this review, mostly from senior citizens in British Columbia, Canada, reference drug pricing can reduce third party drug expenditures by inducing a shift in drug use towards less expensive drugs. We found no evidence of adverse effects on health and no clear evidence of increased health care utilisation.

Original language	English
Pages (from-to)	2-8
Number of pages	7
Journal	Regulatory Rapporteur
Volume	3
Issue number	10
Publication status	Published - Oct 2006

Keywords

pharmaceutical policies
drug pricing
reference pricing

Access to Document

http://www.topra.org/regulatory-rapporteur-october-2006

Cite this

@article{707b5d64885e40c584c6df46a551fa64,

title = "The effects of reference pricing and other drug pricing policies",

abstract = "We carried out a systematic review on studies of effects of pharmaceutical pricing policies. Ten studies of reference pricing and one study of index pricing were included. Based on the evidence in this review, mostly from senior citizens in British Columbia, Canada, reference drug pricing can reduce third party drug expenditures by inducing a shift in drug use towards less expensive drugs. We found no evidence of adverse effects on health and no clear evidence of increased health care utilisation.",

keywords = "pharmaceutical policies, drug pricing, reference pricing",

author = "Morten Aaserud and Dahlgren, {Astrid A.} and Kosters, {Jan Peter} and Heidrun Strum and Ramsay, {Craig R} and Oxman, {Andrew D.}",

year = "2006",

month = oct,

language = "English",

volume = "3",

pages = "2--8",

journal = "Regulatory Rapporteur",

issn = "1742-8955",

publisher = "TOPRA",

number = "10",

}

TY - JOUR

T1 - The effects of reference pricing and other drug pricing policies

AU - Aaserud, Morten

AU - Dahlgren, Astrid A.

AU - Kosters, Jan Peter

AU - Strum, Heidrun

AU - Ramsay, Craig R

AU - Oxman, Andrew D.

PY - 2006/10

Y1 - 2006/10

N2 - We carried out a systematic review on studies of effects of pharmaceutical pricing policies. Ten studies of reference pricing and one study of index pricing were included. Based on the evidence in this review, mostly from senior citizens in British Columbia, Canada, reference drug pricing can reduce third party drug expenditures by inducing a shift in drug use towards less expensive drugs. We found no evidence of adverse effects on health and no clear evidence of increased health care utilisation.

AB - We carried out a systematic review on studies of effects of pharmaceutical pricing policies. Ten studies of reference pricing and one study of index pricing were included. Based on the evidence in this review, mostly from senior citizens in British Columbia, Canada, reference drug pricing can reduce third party drug expenditures by inducing a shift in drug use towards less expensive drugs. We found no evidence of adverse effects on health and no clear evidence of increased health care utilisation.

KW - pharmaceutical policies

KW - drug pricing

KW - reference pricing

M3 - Article

VL - 3

SP - 2

EP - 8

JO - Regulatory Rapporteur

JF - Regulatory Rapporteur

SN - 1742-8955

IS - 10

ER -

The effects of reference pricing and other drug pricing policies

Abstract

Keywords

Access to Document

Fingerprint

Cite this